<DOC>
	<DOCNO>NCT02150213</DOCNO>
	<brief_summary>To provide medical follow-up patient expose BGG492 28 day study CBGG492A2207 ( NCT 01147003 ) and/or CBGG492A2212 ( NCT 01338805 ) .</brief_summary>
	<brief_title>Medical Safety Follow-up Study Patients Who Received More Than 28 Days Total Exposure BGG492</brief_title>
	<detailed_description>The purpose study provide medical follow-up patient expose BGG492 28 day study CBGG492A2207 ( NCT 01147003 ) and/or CBGG492A2212 ( NCT 01338805 ) . Data study CBGG492A2216 use support clinical safety assessment BGG492 regard observance uterine endometrial stromal tumor adrenal cortical adenoma least one year completion BGG492 treatment .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Sarcoma , Endometrial Stromal</mesh_term>
	<mesh_term>Adrenocortical Adenoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Written inform consent obtain assessment perform ; 2 . Patients cooperative , willing participate study assessment , able report AEs ( adverse event ) caregiver record report event ; 3 . Total exposure BGG492 treatment Study BGG492A2207 and/or BGG492A2212 great 28 day 4 . At least 1 year elapse since patient receive last dose BGG492 . There exclusion criterion study . All patient meet inclusion criterion eligible participate followup safety assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adrenocortical Adenoma ,</keyword>
	<keyword>Endometrial Stromal sarcoma</keyword>
	<keyword>BGG492</keyword>
</DOC>